Company intelligence / Profile preview

Petrichor Opportunities Fund I

New York, New York, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Petrichor Opportunities Fund I is a $410 million oversubscribed fund closed in 2020 to back growth-stage healthcare companies, particularly in biopharmaceuticals, medical technology, and diagnostics; Petrichor has not reported clinical results as it is a fund, but its portfolio includes late-stage and commercial companies with positive trial results like ITM-11 (radiopharmaceutical, Phase 3) and pacibekitug (antibody, Phase 2)

Industry: Investors

Partnerships

Frequent co-investments with limited partnersstrategic support to portfolio companieshighlighted acquisition and collaboration events in portfolio: Lantheus/Evergreen TheragnosticsAlcon/Aurion Biotech

Beyond the preview

Go deeper on Petrichor Opportunities Fund I.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Petrichor Opportunities Fund I.

Explore the full profile